SUBSCRIBE
SUBSCRIBE
News   FDA

U.S. Clears Novartis AG Malaria Drug, Awards Voucher

April 8, 2009 | 
1 min read
WASHINGTON, April 8 (Reuters) - U.S. health officials approved a Novartis AG (NOVN.VX) malaria drug on Wednesday and awarded the company a voucher to speed approval of a future medicine.
FDA Approvals
Novartis
MORE ON THIS TOPIC
FDA
Webinar: FDA in 2025: Navigating an Uncertain Regulatory Future
November 5, 2025
 · 
1 min read
 · 
Jef Akst
FDA Headquarters_Grandbrothers/Adobe Stock
Rare diseases
FDA Overruled Reviewers in Approving Stealth’s Barth Syndrome Treatment
November 5, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
 · 
1 min read
 · 
Heather McKenzie
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
November 5, 2025
 · 
2 min read
 · 
Tristan Manalac